Elicio Therapeutics (ELTX) Total Current Liabilities (2020 - 2026)

Elicio Therapeutics (ELTX) has 7 years of Total Current Liabilities data on file, last reported at $7.2 million in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities fell 36.66% year-over-year to $7.2 million; the trailing twelve-month figure through Mar 2026 stood at $7.2 million (down 36.66% YoY), and the FY2025 full-year result was $8.1 million, down 29.62% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $7.2 million, down from $8.1 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $11.5 million in Q4 2024 and bottomed at $2.0 million in Q1 2023.
• The 5-year median for Total Current Liabilities is $8.1 million (2025), against an average of $8.3 million.
• The widest annual swing landed in 2023, when Total Current Liabilities plunged 80.44%; it then jumped 193.01% in 2024.
• A 5-year view of Total Current Liabilities shows it stood at $6.9 million in 2022, then soared by 42.04% to $9.8 million in 2023, then advanced by 18.12% to $11.5 million in 2024, then retreated by 29.62% to $8.1 million in 2025, then retreated by 10.86% to $7.2 million in 2026.
• The last three Total Current Liabilities figures came in at $7.2 million (Q1 2026), $8.1 million (Q4 2025), and $6.5 million (Q3 2025), per Business Quant data.

Peer Comparison